Tech Company Financing Transactions
NX Pharmagen Technologies Funding Round
NX Pharmagen Technologies closed a $17 million Series A financing round on 12/3/2012. Backers included Boehringer Ingelheim Venture Fund, Mitsui & Co. and Shire Pharmaceuticals.
Transaction Overview
Company Name
Announced On
12/3/2012
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
Proceeds Purpose
The company will use the financing to start clinical trials of its biopharmaceutical candidates.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
26679 Agoura Rd. 100
Calabasas, CA 91302
USA
Calabasas, CA 91302
USA
Phone
Website
Email Address
Overview
ArmaGen is a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Callaway
Chief Scientific Officer
William Pardridge
VP - Bus. Development
Derek Kelaita
VP - R & D
Ruben Boado
VP - Regulatory Affairs
Douglas Hunt
Browse more venture capital transactions:
Prev: 12/3/2012: 1stdibs venture capital transaction
Next: 12/3/2012: NanoString Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs